Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar products. It is part of the privately-owned international pharmaceutical group, Alvin Global Life Science. Alvotech was founded in 2013 and is headquartered in Reykjavik, Iceland. The company's mission is to provide patients worldwide with easier and more affordable access to high-quality, life-changing biopharmaceutical products.
Alvotech's robust pipeline primarily focuses on therapeutic areas such as autoimmunity, dermatology, oncology, ophthalmology, and inflammatory diseases. The company engages in robust, fully integrated in-house capabilities from cell line development to commercial manufacturing. This underscores the company's vertical integration, which is reflective of its commitment to those they provide.
The cornerstone of Alvotech is located in a state-of-the-art biopharmaceutical facility in Reykjavik, where products are developed and manufactured. Furthermore, Alvotech has a strong presence not only in Europe but also in Asia, North, and South America.
Alvotech’s visionary leader, Robert Wessman, has been instrumental in driving its fast-paced growth and establishing strategic partnerships to expand the company's global footprint. Driven by a team of international industry veterans, scientists, and biotech experts, the collective experience and knowledge have led to significant progress and milestones for Alvotech in a short span of time.
Alvotech's commitment to innovation is matched by its dedication to quality. The company operates strictly within the guidelines and regulations prescribed by international health authorities such as the EMA (European Medicines Agency), FDA (Food and Drug Administration), and PMDA (Pharmaceuticals and Medical Devices Agency) in Japan. These robust quality controls combine with their rigorous development process to ensure the safety and efficacy of all their products.
Alvotech prides itself on its steadfast commitment to improve patient accessibility to biological therapies. By providing high-quality, similar biological medicinal products at competitive prices, Alvotech has positioned itself as a key player in the global biosimilar market. Guided by a vision of transforming the lives of patients worldwide, Alvotech continues to drive change within the biopharmaceutical industry through innovation, quality, and a patient-centered approach.
This commitment to excellence and patient care has positioned Alvotech as an emerging leader in the biosimilars industry. With its integrated capabilities, expansive biosimilar pipeline, and global distribution network, Alvotech is well positioned to make a significant impact on global healthcare. Through its endeavour, Alvotech emphasises the importance of enabling access to advanced biological medication, confirming its place as a forward-thinking key player in the biopharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alvotech (NASDAQ:ALVO) shares increased by 3.5% on Thursday, closing at $6.0130, despite an 85% drop in trading volume compared to its average session. The biopharmaceutical company reported quarterly revenue of $106 million, surpassing estimates, but missed earnings expectations with an adjusted loss of $0.11 per share. Analysts generally have a "Moderate Buy" rating for Alvotech, with a consensus price target of $8.50.
Alvotech (ALVO) shares experienced a 7% increase in afternoon trading on Wednesday following a double upgrade from Barclays. The article, originating from MT Newswires, provides this brief market update. Further details are restricted to premium subscribers of Yahoo Finance Gold or Silver plans.
Alvotech (NASDAQ:ALVO) shares recently surged by 7.2% to $5.7250, reaching a market capitalization of $1.80 billion. Despite exceeding revenue expectations with $106 million in its latest quarter, the biopharmaceutical company remains unprofitable, reporting a net margin of -36.31%. Analysts currently hold a "Moderate Buy" consensus rating for Alvotech, with an average price target of $8.50, though some firms have downgraded their ratings.
Alvotech (NASDAQ:ALVO) shares rose 5.6% after Barclays upgraded its rating from Underweight to Overweight and doubled its price target from $4.00 to $8.00. The upgrade was driven by a positive outcome from a US FDA inspection at Alvotech's manufacturing facility, which led to a Voluntary Action Indicated (VAI) classification. This development has cleared the path for the resubmission of several biosimilar applications, with regulatory decisions expected in late 2026 and early 2027.
Barclays upgraded Alvotech (NASDAQ: ALVO) after the U.S. FDA issued a Voluntary Action Indicated (VAI) classification for its manufacturing facility in Iceland, removing a significant regulatory hurdle. This clears the path for several biosimilar product approvals, including AVT05, AVT06, and AVT16, with decisions expected in late 2026 and early 2027. The upgrade reflects improved investor sentiment as the company addresses previous concerns regarding financial flexibility and regulatory uncertainties.
Certain ordinary shares of Alvotech are subject to a lock-up agreement that began on June 15, 2026, and will end on September 14, 2026, lasting for 91 days. During this period, executive officers, directors, and specific security holders are restricted from selling or transferring their ordinary shares or related securities without consent. This agreement aims to prevent market instability during the lock-up period.
Citadel Advisors LLC has invested $6.38 million in Alvotech (NASDAQ:ALVO), acquiring 1.73 million shares and taking a 0.57% stake. Several other institutional investors also adjusted their positions in the biopharmaceutical company. Despite mixed analyst ratings, Alvotech recently reported quarterly revenue of $106 million, exceeding estimates, though its loss per share was wider than anticipated.